Results of the Phase 1 dose-escalation cohort of the Phase 1/2 ARIA study evaluating MYB mRNA degrader, REM-422, in patients with recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC), will be highlighted in an oral presentation at the 2026 ASCO Annual Meeting.
bit.ly/4eyP6ht
#ASCO26 #REM422
“Targeting MYB with REM-422 for the treatment of pediatric T-cell acute lymphoblastic leukemia - A report from the Pediatric Preclinical Testing Consortium (PIVOT)” will be featured in an oral presentation at the #AACR26 meeting.
#RNAtherapeutics #REM422
We are looking to build on the positive initial results evaluating our first-in-class MYB RNA degrader, REM-422, in patients with recurrent or metastatic ACC. Our Phase 1/2 clinical trial is open and enrolling, learn more here: bit.ly/4oXyim2
#REM-422 #AdeonoidCysticCarcinoma #OncologyResearch
April is head and neck cancer awareness month and for people living with the rare cancer of the salivary glands, ACC, options are few with no FDA approved therapies. We are working to change that. Learn more about REM-422 and our progress in ACC.
Remix will be at the Drug Discovery Chemistry Conference! Our Chief Science Officer, Dom Reynolds, PhD, will be leading a session and breakout discussion on Emerging Modalities for Degradation and presenting on “Strategies to Drug RNA-Protein Complexes with Small Molecules.”
We’re pleased to announce that the U.S. FDA has granted Fast Track designation to first-in-class, small molecule MYB mRNA degrader, REM-422, for the treatment of recurrent, metastatic, or unresectable ACC.
bit.ly/4rC0UT5
#REM422 #AdenoidCysticCarcinoma
On #IWD2026, we recognize the women who have made progress on behalf of patients worldwide, including our team, who are building a company at the forefront of tackling diseases by modulating RNA with small molecules and addressing disease drivers at their source. #RemixTherapeutics
Fred Vaillancourt, PhD, will be presenting at the ASBMB meeting, highlighting the science behind Remix’s leadership in pioneering a new class of RNA therapeutics with the unique ability to modify RNA processing and target disease upstream of protein expression.
#ASBMB26
We’re wearing stripes to stand with patients facing rare cancers. Making progress for patients with minimal or no approved treatment options, including rare cancers like ACC and AML is why Remix was founded.
Learn more: bit.ly/485hLGm
#RareDiseaseDay #ShowYourStripes
Remix’s Co-Founder and CEO was recently featured in Pharmaceutical Technology, highlighting how modulating RNA processing can dramatically expand the universe of druggable targets.
Read the article by Jam Bensilum here: bit.ly/4aKtGdL
#REM422 #RNAdegradation #RNAdegraders #RNAtherapeutics
We’re looking forward to sharing how Remix is advancing a pipeline of innovative therapeutics in Oncology, uniquely designed to control RNA processing pathways and address disease drivers at their source at the Leerink Partners Global Healthcare Conference.
#LeerinkGlobalHealthcare
Welcome Chip Michaud, Vice President of Finance, & Hayley Amemiya, Senior Scientist, Bioinformatics & Data Science, to Remix! Their leadership and experience will help us advance our next stage of growth addressing the intractable drivers of disease.
#RemixTherapeutics
Amy Siu, MS, Remix’s Head of DMPK will be presenting at the upcoming SLAS 2026 Conference and Exhibition! Amy will be highlighting the role of physiologically based pharmacokinetic modeling in discovery and early nonclinical development.
Learn more: bit.ly/4qkuTyj
Today, on World Cancer Day, we join the community #UnitedByUnique because behind every diagnosis is a deeply personal story. Through our work in Adenoid Cystic Carcinoma and AML, we hope to make meaningful progress on behalf of patients and their families. #WorldCancerDay
Kicking off our team fundraiser in support of the SCN8A Research Fund, to help make a real impact for patients affected by SCN8A-related epilepsy and neurodevelopmental disorders.
Learn more: bit.ly/4k7FFq7
#RareDiseaseResearch#RemixTherapeutics #Community
Our Women’s Networking Group Book Club met to discuss The Elements of Marie Curie, focusing on her deep commitment to mentoring & encouraging women to pursue careers in science, reinforcing our commitment to developing the next generation of scientists at every stage.
Today, we announced the appointment of Mythili Koneru, MD, PhD, as our Chief Medical Officer, leading clinical development, medical strategy, and regulatory engagement.
#mRNA #RNAdegradation #RNAdegraders #RNAtherapeutics #OncologyResearch #RemixTherapeutics
Read the PR here: bit.ly/4qJply4
The Remix Therapeutics team will be at the JP Morgan 2026 Healthcare Conference January 12-15.
Reach out to schedule a meeting: info@remixtx.com
See you in San Francisco!
#JPM2026
ACC is a cancer of salivary glands, typically originating in the head and neck region. A growing body of research, including our work with REM-422, highlights the importance of addressing MYB, a previously intractable driver, in diseases like ACC.
More here: bit.ly/4oXyim2
Remix will be attending the upcoming virtual RBC Capital Markets Healthcare Private Company Conference. Our CEO, Pete Smith, will be presenting on Dec 11th at 1:20 PM and will be joined by, CBO, Heather Wasserman, for investor meetings. #RBCHealthcare #RemixTherapeutics
Join us in supporting local organizations making a difference in our community, like MGH Caring for a Cure, offering support for patients & advancing life-saving research, & Rosie’s Place, providing safety & hope for women experiencing homelessness for 50+ years.
Our CSO, Dom Reynolds, PhD, will be highlighting the development of REM-422 for ACC, AML, and high-risk MDS and how our REMaster™ platform is advancing RNA-targeted drug discovery at the 8th RNA-Targeted Drug Discovery & Development Summit. #REM422 #mRNA #RemixTherapeutics
Our CEO, Pete Smith, PhD, will be attending the London Growth Summit, hosted by LifeSci Capital and
Sofinnova Partners. Pete Smith, PhD, CEO, and Heather Wasserman, CBO, will be attending Jefferies
Global Healthcare Conference. #JefferiesHealthcare #RemixTherapeutics
Our Co-Founder and CEO, Pete Smith, will present a corporate overview at the Guggenheim Second Annual Healthcare Innovation Conference on November 10 at 2:15 PM ET. The Remix management team will also be hosting one-on-one meetings with investors.
➡️https://bit.ly/4qEuRml
Our Co-Founder and CEO, Pete Smith, and Chief Business Officer, Heather Wasserman, will be participating in the Wells Fargo Virtual Private Biopharma Symposium on November 5.
If you would like to schedule a meeting, please reach out to: info@remixtx.com. #RemixTherapeutics
Announcing positive preliminary results from ongoing Phase 1 clinical trial evaluating first-in-class MYB RNA degrader, REM-422, in patients with R/M adenoid cystic carcinoma at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. #Targets25
bit.ly/4ozZes8
Next week at the 8th Annual TPD & Induced Proximity Summit in Boston, our Chief Scientific Officer, Dom Reynolds, PhD, will be chairing a panel on “Next Gen Novel Molecular Glue Discovery” and presenting on “Strategies to Drug RNA-Protein Complexes with Small Molecules.”
Our MYB RNA degrader, REM-422, will be featured in late-breaking oral and poster presentations and in a session on targeting RNA with small molecules at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. #Targets25
➡️ bit.ly/48u70iy
Join us next week for the @bloodcancerunited.bsky.social Light the Night Boston! We will be walking with thousands of others to honor those affected by blood cancers for greater awareness, research & support. #LightTheNight #LLS #RemixTherapeutics
Learn more: bit.ly/3VVRuo8
Our CSO, Dom Reynolds, breaks down the science behind Remix’s pioneering new approach to treating difficult to drug diseases by targeting the cellular complexes that process RNA & working upstream of conventional therapeutic approaches.
➡️ More here: bit.ly/3VGrT2o
